Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

OMT Announces OmniRat™ Collaboration with CNA Development LLC

Published: Monday, December 24, 2012
Last Updated: Monday, December 24, 2012
Bookmark and Share
OMT to employ its OmniRat™ transgenic animal platform to generate human antibodies.

Open Monoclonal Technology, Inc. (OMT) has announced a discovery collaboration with CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc.

OMT will employ its OmniRat™ transgenic animal platform to generate human antibodies with great specificity, affinity and manufacturability.

OmniRat™ enables developers to skip the need to humanize animal-derived antibodies before initiating preclinical pharmacokinetic evaluations of their compounds.

Dr. Roland Buelow, Founder and CEO of OMT, said: "OmniRat makes antibodies with fully human idiotypes as well as normal rats make normal rat antibodies. We look forward to making the technology available to Janssen, one of the pioneers and leaders in therapeutic human antibodies."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCT and OMT Announce Human Antibody Discovery and Development Collaboration
OMT will use OmniRat™ transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT.
Tuesday, December 04, 2012
Trellis and OMT Announce Therapeutic Antibody Discovery Collaboration
Companies will join forces to generate human antibodies against therapeutic targets using OMT’s OmniRat™ platform.
Tuesday, October 09, 2012
OMT Announces New Antibody Discovery Program
Open Monoclonal Technology collaborate with Merck KGaA.
Tuesday, July 10, 2012
Scientific News
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Fighting Cancer with the Power of Immunity
Researchers at MIT have used a combination of four different therapies to activate both of the immune system’s two branches, producing a coordinated attack that led to the complete disappearance of large, aggressive tumors in mice.
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Immunotherapy Technique Holds Promise for Curing Food Allergies
Scientists develop immunotherapy technique that almost eliminating allergic response and anaphylactic response in food-allergic mice.
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Antibodies from Ebola Survivors Neutralize Virus, Protect Lab Mice
Scientists discover antiboides generated from the blood of Ebola survivors can strongly combat the virus in the lab.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Using CRISPR to Accelerate Search for HIV Cure
Gene-editing platform makes it easier to create HIV-resistant immune cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos